Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 7 | 2025 | 899 | 0.890 |
Why?
|
| Immunological Synapses | 1 | 2025 | 30 | 0.890 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 61 | 0.880 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 120 | 0.850 |
Why?
|
| Surgery Department, Hospital | 1 | 2021 | 21 | 0.710 |
Why?
|
| Infection Control | 1 | 2021 | 157 | 0.640 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 98 | 0.620 |
Why?
|
| T-Lymphocytes | 7 | 2025 | 1754 | 0.580 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 499 | 0.510 |
Why?
|
| Pandemics | 2 | 2022 | 1185 | 0.440 |
Why?
|
| Sarcoma | 2 | 2025 | 207 | 0.380 |
Why?
|
| Immunotherapy | 1 | 2016 | 748 | 0.340 |
Why?
|
| Oocytes | 2 | 2024 | 290 | 0.330 |
Why?
|
| Egypt | 3 | 2022 | 30 | 0.270 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3682 | 0.260 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2025 | 266 | 0.250 |
Why?
|
| Endoglin | 1 | 2025 | 32 | 0.240 |
Why?
|
| Zona Pellucida Glycoproteins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 26 | 0.230 |
Why?
|
| CD28 Antigens | 1 | 2025 | 81 | 0.220 |
Why?
|
| Luminescence | 2 | 2022 | 18 | 0.210 |
Why?
|
| Granulosa Cells | 1 | 2024 | 140 | 0.210 |
Why?
|
| Seasons | 1 | 2024 | 327 | 0.200 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 2022 | 5 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 271 | 0.180 |
Why?
|
| Groundwater | 1 | 2021 | 9 | 0.180 |
Why?
|
| Neoplasms | 1 | 2016 | 2952 | 0.180 |
Why?
|
| Water Pollutants, Chemical | 1 | 2021 | 41 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 241 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 161 | 0.160 |
Why?
|
| Quartz | 1 | 2020 | 1 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 25 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 258 | 0.160 |
Why?
|
| Triage | 1 | 2021 | 149 | 0.160 |
Why?
|
| Oogenesis | 1 | 2020 | 55 | 0.160 |
Why?
|
| Laminin | 1 | 2020 | 72 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 98 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2025 | 992 | 0.160 |
Why?
|
| Temperature | 1 | 2020 | 302 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 183 | 0.150 |
Why?
|
| Health Policy | 1 | 2021 | 233 | 0.150 |
Why?
|
| Riboflavin | 1 | 2018 | 27 | 0.150 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 52 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 450 | 0.150 |
Why?
|
| Lasers, Excimer | 1 | 2018 | 69 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2018 | 41 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 188 | 0.140 |
Why?
|
| Keratoconus | 1 | 2018 | 47 | 0.140 |
Why?
|
| Photorefractive Keratectomy | 1 | 2018 | 69 | 0.140 |
Why?
|
| Ependymoma | 1 | 2020 | 177 | 0.140 |
Why?
|
| Transcriptome | 1 | 2024 | 1122 | 0.140 |
Why?
|
| Ovary | 1 | 2020 | 369 | 0.130 |
Why?
|
| Collagen | 1 | 2018 | 303 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 565 | 0.120 |
Why?
|
| Humans | 15 | 2025 | 132064 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 164 | 0.120 |
Why?
|
| Medulloblastoma | 1 | 2020 | 571 | 0.110 |
Why?
|
| Telemedicine | 1 | 2021 | 495 | 0.110 |
Why?
|
| Animals | 8 | 2025 | 34804 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 294 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2025 | 4710 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1404 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 2647 | 0.080 |
Why?
|
| Mice | 5 | 2025 | 18478 | 0.080 |
Why?
|
| Female | 8 | 2025 | 70664 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2024 | 13000 | 0.060 |
Why?
|
| Single-Chain Antibodies | 1 | 2025 | 44 | 0.060 |
Why?
|
| Vidarabine | 1 | 2024 | 80 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 132 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 126 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.050 |
Why?
|
| Cattle | 1 | 2024 | 569 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 80 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 686 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2022 | 34 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 426 | 0.050 |
Why?
|
| Immunoassay | 1 | 2022 | 135 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4684 | 0.050 |
Why?
|
| Hydrology | 1 | 2021 | 1 | 0.050 |
Why?
|
| Water Movements | 1 | 2021 | 3 | 0.050 |
Why?
|
| Pyrroles | 1 | 2023 | 182 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2025 | 518 | 0.040 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 90 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 6570 | 0.040 |
Why?
|
| Spermatocytes | 1 | 2020 | 24 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 60 | 0.040 |
Why?
|
| Nuclear Envelope | 1 | 2020 | 20 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2020 | 60 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 42 | 0.040 |
Why?
|
| Crystallization | 1 | 2020 | 89 | 0.040 |
Why?
|
| Meiosis | 1 | 2020 | 116 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 358 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 803 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2020 | 294 | 0.040 |
Why?
|
| Germ Cells | 1 | 2020 | 204 | 0.040 |
Why?
|
| Transgenes | 1 | 2020 | 335 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 223 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 588 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 552 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2018 | 35 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 500 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1045 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 861 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2018 | 197 | 0.040 |
Why?
|
| Corneal Topography | 1 | 2018 | 154 | 0.030 |
Why?
|
| Testis | 1 | 2020 | 422 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 800 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 402 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 807 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 722 | 0.030 |
Why?
|
| Refraction, Ocular | 1 | 2018 | 217 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1732 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 1204 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2020 | 461 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2020 | 1017 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1560 | 0.030 |
Why?
|
| Male | 4 | 2024 | 64938 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2018 | 707 | 0.030 |
Why?
|
| Cornea | 1 | 2018 | 569 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 2447 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1365 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2020 | 2679 | 0.030 |
Why?
|
| Prognosis | 1 | 2022 | 5010 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3865 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 31571 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3403 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5412 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21426 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 13048 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 9952 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17389 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14734 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 28993 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 20542 | 0.010 |
Why?
|
| Child | 1 | 2020 | 25763 | 0.010 |
Why?
|